Advertisement

VP7 from African horse sickness virus serotype 9 protects mice against a lethal, heterologous serotype challenge

  • A. M. Wade-Evans
  • L. Pullen
  • C. Hamblin
  • R. S. O’Hara
  • J. N. Burroughs
  • P. P. C. Mertens
Conference paper

Summary

An established mouse model system was used to evaluate the effectiveness of the major outer core protein VP7 of African horse sickness virus (AHSV) serotype 9 as a subunit vaccine. Balb C mice were immunised with VP7 crystals purified from AHSV infected BHK cells. In groups of mice, each of which was immunised with ≥ 1.5 µg of the protein in Freund’s adjuvant, ≥ 80% of mice survived challenge with a virulent strain of a heterologous AHSV serotype (AHSV 7), that killed ≥ 80% of the mice in the uninoculated control groups. This level of protection was significantly greater than that observed in mice inoculated with equivalent amounts of either denatured VP7 (50% survival), or GST/VP7 fusion protein (50–70% survival), or which were vaccinated with AHSV 9 (40–50% survival). The VP7 protein folding, or its assembly into crystals, are thought to play some role in the effectiveness of the protective response observed. Titres of circulating antibodies against AHSV VP7 were determined by competitive ELISA but did not appear to correlate with the levels of protection observed. Passive transfer of these antibodies to syngeneic recipients also failed to protect Balb C mice from the AHSV 7 challenge. The observed protection is therefore unlikely to be due to an antibody mediated immune response.

Keywords

Subunit Vaccine Competitive ELISA Virus Serotype Bluetongue Virus Single Inoculation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson J, Mertens PPC, Herniman KAJ (1993) A competitive ELISA for the detection of anti-tubule antibodies using a monoclonal antibody against bluetongue virus non-structural protein NS1. J Virol Methods 43: 167–176PubMedCrossRefGoogle Scholar
  2. 2.
    Angove HL, Wade-Evans AM, Burroughs JN, Mertens PPC, Parkhouse RME, Takamatsu H (1998) Immunodominant helper T-cell epitopes recognised by sheep are arranged as a cluster in the amino-acid sequence 202–253 of outer capsid protein VP2 from bluetongue virus serotype 1 from South Africa (manuscript in preparation)Google Scholar
  3. 3.
    Borden EC, Shope RE, Murphy FA (1971) Physiochemical and morphological relationships of some arthropod bourne viruses to bluetongue virus — a new taxonomic group. Physiochemical and serological studies. J Gen Virol 13: 261–271PubMedCrossRefGoogle Scholar
  4. 4.
    Burroughs JN, O’Hara RS, Smale CJ, Hamblin C, Walton A, Armstrong R, Mertens PPC (1994) Purification and properties of virus particles, infectious sub viral particles, cores and VP7 crystals of African Horse sickness virus serotype 9. J Gen Virol 75: 1849–1857PubMedCrossRefGoogle Scholar
  5. 5.
    Cowley JA, Gorman BM (1989) Cross neutralisation of genetic reassortants of blue-tongue virus serotypes 20 and 21. Vet Microbiol 19: 37–51PubMedCrossRefGoogle Scholar
  6. 6.
    Hamblin C, Graham SC, Anderson EC, Crowther JR (1990) A competitive ELISA for the detection of group specific antibodies to African horse sickness virus. Epidemiol Infect 104: 303–312PubMedCrossRefGoogle Scholar
  7. 7.
    Hamblin C, Mertens PPC, Mellor PS, Burroughs JN, Crowther JR (1991) A serotype specific enzyme-linked immunosorbent assay (ELISA) for the detection and identification of African horse sickness viruses. J Virol Methods 31: 285–292PubMedCrossRefGoogle Scholar
  8. 8.
    Holmes IH, Boccardo G, Estes MK, Furuichi MK, Hoshino Y, Joklik WK, McCrae M, Mertens PPC, Milne RG, Samal KSK, Shikata E, Winton JR, Uyeda I (1995) Family Reoviridae. In: Murphy FA, Fauquet CM, Bishop DHL, Ghabrial SA, Jarvis AW, Martelli GP, Mayo MA, Summers MD (eds) Virus Taxonomy. Classification and Nomenclature of Viruses. Sixth Report of the International Committee on Taxonomy of Viruses. Springer, Wien New York, pp 208–237 (Arch Virol [Suppl] 10)Google Scholar
  9. 9.
    House JA (1998) Future international management of African horse sickness vaccines. In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York (Arch Virol [Suppl] 14)Google Scholar
  10. 10.
    Howell PG (1962) The isolation and identification of further antigenic types of African horse sickness virus. Onderstepoort J Vet Res 29: 139–149Google Scholar
  11. 11.
    Jeggo MH, Wardley RC, Brownlie J (1984) A study of the role of cell-mediated immunity in bluetongue virus infection of sheep, using cellular adoptive transfer techniques. Immunology 52: 403–410PubMedGoogle Scholar
  12. 12.
    Kärber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 162: 480–483CrossRefGoogle Scholar
  13. 13.
    Martin LA, Meyer AJ, O’Hara RS, Fu H, Knowles NJ, Mertens PPC (1998) Phylogenetic analysis of African horse sickness virus genome segment 10: sequence variation involved in virus release and virulence characteristics. In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York (Arch Virol [Suppl] 14)Google Scholar
  14. 14.
    Mertens PPC, Pedley S, Cowley J, Burroughs JN, Corteyn AH, Jeggo MH, Jennings AM, Gorman BM (1989) Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype. Virology 170: 561–565PubMedCrossRefGoogle Scholar
  15. 15.
    McIntosh BM (1958) Immunological types of horse sickness virus and their significance in immunisation. Onderstepoort J Vet Res 27: 465–538Google Scholar
  16. 16.
    Nuttal PA, Jacobs SC, Jones LD, Carey D, Moss SR (1992) Enhanced neurovirulence of tick bourne orbiviruses resulting from genetic modulation. Virology 187: 407–412CrossRefGoogle Scholar
  17. 17.
    O’Hara RS (1994) Identification of the genome segments and proteins controlling the virulence of African horse sickness virus. Thesis submitted in part for the degree of doctor of Philosophy, University of ReadingGoogle Scholar
  18. 18.
    O’Hara RS, Meyer AJ, Pullen L, Martin LA, Mertens PPC (1998) Development of a mouse model system and identification of the individual genome segments of African horse sickness virus serotypes 3 and 8 involved in determination of virulence. In: Mellor PS, Baylis M, Hamblin C, Calisher CH, Mertens PPC (eds) African horse sickness. Springer, Wien New York, pp 259–279 (Arch Virol [Suppl] 14)Google Scholar
  19. 19.
    Roy P (1995) Towards the control of African horse sickness by recombinant technology. In: Nakajima H, Plowright W (eds) Equine infectious diseases VII (Proceedings of the Seventh International Conference). R&W Publications, Newmarket, pp 65–70Google Scholar
  20. 20.
    Roy P, Hirasawa T, Fernandez M, Blinov VM, Sanchez-Vizcaino JM (1991) The complete sequence of the group-specific antigen, VP7, of African horse sickness disease virus serotype 4 reveals a close relationship to bluetongue virus. J Gen Virol 72: 1237–1241PubMedCrossRefGoogle Scholar
  21. 21.
    Taylor MB, van der Meyden CH, Erasmus BJ, Reid RR, Labuschagne JH, Dreyer L, Prozesky OW (1992) Encephalitis and chorioretinitis associated with neurotropic African horse sickness virus infection in laboratory workers. Part IV. Experimental infection of the veruet monkey Cercopithecus pygerythrus. S Afr Med J 81: 462–467PubMedGoogle Scholar
  22. 22.
    Wade-Evans AM, Woolhouse T, O’Hara R, Hamblin C (1993) The use of African horse sickness virus VP7 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA. J Virol Methods 45: 179–188PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • A. M. Wade-Evans
    • 1
  • L. Pullen
    • 1
  • C. Hamblin
    • 1
  • R. S. O’Hara
    • 1
  • J. N. Burroughs
    • 1
  • P. P. C. Mertens
    • 1
  1. 1.Pirbright LaboratoryInstitute for Animal HealthWoking, SurreyUK

Personalised recommendations